We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.00 | -1.62% | 121.40 | 122.20 | 123.40 | 123.20 | 121.00 | 121.80 | 212,338 | 16:35:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -14.67 | 821.42M |
From Apr 2019 to Apr 2024
TIDMSYNC
RNS Number : 9463S
Syncona Limited
11 November 2019
11 November 2019
Notice of Interim Results
Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, expects to announce its interim financial results for the six months ended 30 September 2019 on Thursday 21 November 2019.
A presentation for analysts will take place at 9.00am GMT and a webcast of the presentation will be available on the Company's website at https://www.synconaltd.com/ or https://webcast.openbriefing.com/syncona-interim2019/
To join via conference call, please dial:
United Kingdom: 0800 640 6441 United Kingdom (Local): 020 3936 2999 All other locations: +44 20 3936 2999 Access code: 379204
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Ben Atwell / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORCKDDQFBDKDDD
(END) Dow Jones Newswires
November 11, 2019 04:00 ET (09:00 GMT)
1 Year Syncona Chart |
1 Month Syncona Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
